Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debio 0123 + carboplatin in advanced solid tumors
NCT03968653Phase 1Terminated
- Sponsor
- Debiopharm
- Start
- Jul 2019
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of zedoresertib in solid tumor (advanced stage) (3 arms), sponsored by Debiopharm. Primary endpoints: Recommended Phase 2 Dose at 45 days, Percentage of Participants with Treatment-Emergent Serious Adverse Events at 46 months and 2 more. Started Jul 2019; status: terminated.
02
Drugs
zedoresertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03968653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03968653.